The cost of the shares Integra LifeSciences Holdings Corporation (IART – Free Report) launched the NeuraGen 3D Nerve Guide Matrix – a resorbable implant for the repair of peripheral nerve discontinuities. NeuraGen 3D is intended for the repair of peripheral nerve discontinuities, whereby cleft closure can be achieved by flexion of the extremity. However, it is important to note that NeuraGen 3D is not recommended for patients with a known history of hypersensitivity to bovine-derived or chondroitin materials.
NeuraGen 3D is the latest addition to Integra’s Peripheral Nerve Repair portfolio. Compared to hollow nerve leads alone, the NeuraGen 3D is specifically designed to generate an optimized environment that allows for a fully functional recovery after mid-lap nerve repair.
The latest start is likely to strengthen the company’s Tissue Technologies business.
Learn more about the benefits of NeuraGen 3D
With the addition of NeuraGen 3D to Integra’s nerve portfolio, surgeons now have access to the latest innovation in peripheral nerve repair. It is the first product that is intelligently designed and developed based on understanding how nerves regenerate. It is expected to help bridge the gap between hollow conduit and allograft.
NeuraGen 3D uses an innovative combination of Integra’s Bovine Type 1 collagen and Integra Dermal Regeneration Template technology. The porous channels of NeuraGen 3D’s unique internal matrix have been pre-clinically demonstrated to guide Schwann cell migration and direct axonal growth, which is an important goal for surgeons to treat nerve repair and restore function.
Image Source: Zacks Investment Research
NeuraGen 3D is a big step forward in the peripheral nerve repair injury treatment. Per management, it is the company’s most innovative and advanced matrix product to reach markets in a few decades. It has the potential to make a significant contribution to patient care.
Industry Perspectives
According to a report published in MarketsandMarkets, the global nerve repair and regeneration market is expected to see a CAGR of 9.1% between 2020 and 2025. Government support for neurological disorders drives the market.
Given the market prospects, Integra’s latest launch for nerve repair comes at an opportune time.
Notable developments in tissue technologies
In the fourth quarter of 2021, Integral Tissue Technologies revenues increased 0.4% year over year on a reported basis and 6.7% on an organic basis. Sales in wound reconstruction have improved 3.8% year over year on an organic basis, driven by Integra Skin and SurgiMend in the company’s burn, trauma and surgical reconstruction markets.
The ACell business stabilized in the fourth quarter, with sales of $ 16.9 million in line with the November lead. The ongoing recovery of customer orders has led to 15% growth in private label sales by 2020.
Stock price performance
The stock has improved its industry over the past six months. It was down 10.4% against the fall of 15.2% of the industry.
Zacks rank and key picks
Currently, Integra has a Zacks Rank # 3 (Hold).
Some are better ranked stocks in the broad medical space Henry Schein, Inc. (HSIC – Free post), McKesson Corporation (MCK – Free report) IDEXX Laboratories, Inc. (IDXX – Free post).
Henry Schein has an estimated long-term growth rate of 11.8%. HSIC’s revenue exceeded estimates in the next four quarters, the average surprise is 25.5%. It currently has a Zacks Rank # 2 (Buy). You can see the full list of today’s Zacks # 1 Rank (Strong Buy) shares here.
Henry Schein has improved the industry over the last year. HSIC gained 34.8% compared to the industry 10.9% increase last year.
McKesson has a long-term revenue growth of 11.8%. MCK’s earnings exceeded estimates in the next four quarters, delivering a surprise of 20.6% on average. It currently has a Zacks Rank # 2.
McKesson has surpassed the industry over the last year. MCK gained 59.8% in the said period compared to the industry’s 10.9% growth.
IDEXX has a long-term revenue growth of 13%. The company’s revenue exceeded estimates in the next four quarters, delivering an average surprise of 18.6%. IDXX currently has a Zacks Rank # 2.
IDEXX has improved its industry over the last year. IDXX gained 16.8% against the 1.2% growth of the industry in the same period.
Add Comment